Who Should Consider PGT-A During IVF?

If you have been told that PGT-A might improve your IVF plan, the next question is usually the hardest one: is it actually right for you? When patients ask who should consider PGT-A, they are rarely asking for a textbook definition. They want to know whether this extra step could meaningfully improve decision-making, reduce uncertainty, or help them move through treatment with more clarity.

PGT-A stands for preimplantation genetic testing for aneuploidy. It is used during IVF to screen embryos for the correct number of chromosomes before transfer. The goal is not to create better embryos, but to help identify which embryos may have a better chance of leading to a healthy pregnancy. That distinction matters, because PGT-A can be useful in some situations and less helpful in others.

Who should consider PGT-A?

The short answer is that PGT-A may be worth discussing for patients who want more information before embryo transfer, especially when age, prior treatment history, or pregnancy loss raises concern about chromosomal abnormalities. It can also be helpful when there are multiple embryos and the question becomes which one to transfer first.

That said, PGT-A is not automatically the best choice for every patient. Fertility care works best when decisions are tailored to your age, ovarian reserve, medical history, number of embryos, and goals for treatment. A recommendation that makes sense for one patient may not make sense for another.

When PGT-A may make the most sense

Patients of advanced maternal age

As egg quality changes with age, the likelihood of embryos having abnormal chromosome numbers tends to rise. For many women in their late 30s or 40s, that becomes one of the biggest reasons to consider PGT-A. In these cases, testing can sometimes help identify embryos that are more likely to implant and less likely to result in miscarriage.

This does not mean PGT-A guarantees success. It simply gives your care team more information when planning embryo transfer. For patients who have already been through disappointment, that added clarity can feel significant.

Patients with recurrent pregnancy loss

Repeated miscarriage is emotionally exhausting, and one possible cause is chromosomal abnormality in the embryo. If you have had multiple pregnancy losses, PGT-A may be part of a more informed IVF strategy. It can help guide the selection of embryos that appear chromosomally normal, which may reduce one important source of risk.

Still, recurrent loss is complex. Uterine factors, hormonal conditions, immune issues, and male factor fertility can all play a role. PGT-A may help, but it should be considered as one part of a broader evaluation rather than the only answer.

Patients with repeated failed IVF transfers

When high-quality embryos have been transferred but pregnancy has not occurred, it is reasonable to ask whether chromosome issues may be part of the picture. For some patients, PGT-A can help distinguish between embryos that look promising under the microscope and those that may have a better biological chance of continuing development.

This can be especially valuable after several unsuccessful cycles, when patients want a more targeted approach and fewer unknowns. At the same time, failed transfers are not always caused by embryo genetics. The uterine lining, timing of transfer, lab conditions, and overall treatment plan also matter.

Patients who produce several embryos

PGT-A is often most helpful when there are multiple embryos available. If you have one embryo, the decision is different than if you have six. With more embryos, testing may help prioritize transfer order and reduce the trial-and-error feeling that many patients want to avoid.

For intended parents who want to build a family over more than one pregnancy, this information can also support longer-term planning. Knowing more about embryo viability can make future transfer decisions more straightforward.

Patients using IVF to reduce uncertainty

Some patients are not coming to IVF after years of failed treatment. They may be starting with IVF because they want as much information as possible from the beginning. In those cases, PGT-A can appeal to people who value data, planning, and a more selective transfer strategy.

This is often true for busy professionals, international patients managing treatment timelines, or anyone who wants to make each transfer as informed as possible. It does not remove uncertainty completely, but it can reduce some of it.

Who may not need PGT-A

Younger patients with a strong prognosis

For younger patients who create only a small number of embryos and have no history of miscarriage or failed IVF, the benefit of PGT-A may be less clear. Many embryos in this group may already have a good chance of implantation, and testing may not significantly change the treatment plan.

That does not mean it should never be considered. It means the value depends on how likely the result is to change what happens next.

Patients with very few embryos

If only one or two embryos are available, testing may provide limited practical benefit. In some cases, the best next step is simply to transfer the embryo rather than add another decision point. This is a nuanced discussion and should be based on your full clinical picture, not a general rule.

Patients in this situation often need compassionate, realistic guidance. More testing is not always better if it does not improve the path forward.

What PGT-A can and cannot tell you

One of the most important parts of deciding who should consider PGT-A is understanding what the test actually does. PGT-A looks at chromosome number. It does not test for every genetic condition, and it does not guarantee that a normal embryo will implant or lead to a live birth.

It also cannot correct problems in an embryo. It is a screening tool, not a treatment. That is why good counseling matters so much. The value of PGT-A comes from how the information is used within a well-designed IVF plan.

There are also gray areas. Some embryos may come back as mosaic, meaning they contain a mix of normal and abnormal cells. Mosaic results can be difficult to interpret and may require a more detailed conversation about risks, transfer options, and next steps. This is one reason patients benefit from working with a team that explains results clearly and does not rush major decisions.

How to decide if PGT-A fits your situation

A good decision about PGT-A starts with a few practical questions. How old are you? Have you had miscarriages before? Have prior IVF cycles failed? How many embryos are likely to be available for testing? Would the result meaningfully change your transfer strategy?

Just as important, how do you personally approach uncertainty? Some patients feel more at ease with additional information. Others prefer a simpler treatment plan unless there is a strong medical reason to add testing. Neither approach is wrong.

This is where individualized fertility care matters most. A thoughtful physician will not present PGT-A as something everyone needs. They will explain where it may help, where the evidence is more mixed, and how it fits your specific goals. For patients traveling for care or coordinating treatment from abroad, that kind of clear guidance can make the process feel much more manageable.

At Dr. Alex Aldape, these conversations are built around the patient, not around a one-size-fits-all protocol. For some families, PGT-A adds confidence and direction. For others, a different approach may be more appropriate.

Questions worth asking before you say yes

Before moving forward, ask your fertility team how PGT-A would affect your treatment plan. Ask whether your age or history makes it more relevant, how many embryos they expect, and what they would recommend if the results include mosaic embryos. You should also ask a simple but essential question: if we do this test, what decisions will it actually help us make?

That question often brings the clearest answer. If the information is likely to shape embryo selection, reduce avoidable transfers, or support a history of pregnancy loss, PGT-A may be a strong option. If it is unlikely to change the next step, it may be less useful.

Fertility treatment asks a lot of patients emotionally and physically. The right plan is not the most aggressive one. It is the one that makes sense for your medical history, your goals, and your need for clarity. If you are wondering who should consider PGT-A, the best next step is a personalized conversation that treats your case as unique, because it is.